Regulatory T Cells in Kidney Transplantation: New Directions?

American Journal of Transplantation

Volumn 15, Issue 9, 2015, Pages 2288-2300

  Braza, F ^a,b,c   Durand, M ^a,b,c   Degauque, N ^b,c   Brouard, S ^b,c  

^a UNIVERSITÉ DE NANTES   (France)

^b Centre National de la Recherche Scientifique   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Basic (laboratory) research science; immunobiology; kidney transplantation nephrology; lymphocyte biology; tolerance: clinical

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

CD4+ CD25+ T LYMPHOCYTE; EPIGENETICS; GRAFT SURVIVAL; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN PROCESSING; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; IMMUNOLOGY; PROGNOSIS;

ANIMALS; HUMANS; IMMUNE TOLERANCE; KIDNEY TRANSPLANTATION; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84939564737     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13395     Document Type: Review

References (136)

1. Janeway CA, Jr., Sharrow SO, Simpson E,. T cell populations with different functions. Nature 1975; 253: 544-546.
2. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M,. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
3. Hall BM, Pearce NW, Gurley KE, Dorsch SE,. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J Exp Med 1990; 171: 141-157.
4. Hori S, Nomura T, Sakaguchi S,. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
5. Fontenot JD, Gavin MA, Rudensky AY,. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
6. Khattri R, Cox T, Yasayko SA, Ramsdell F,. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4: 337-342.
7. Bennett CL, Christie J, Ramsdell F, et al., The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20-21.
8. Waldmann H, Graca L, Cobbold S, Adams E, Tone M, Tone Y,. Regulatory T cells and organ transplantation. Semin Immunol 2004; 16: 119-126.
9. Waldmann H, Hilbrands R, Howie D, Cobbold S,. Harnessing FOXP3+ regulatory T cells for transplantation tolerance. J Clin Invest 2014; 124: 1439-1445.
10. Wood KJ, Sakaguchi S,. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210.
11. Ferrer IR, Hester J, Bushell A, Wood KJ,. Induction of transplantation tolerance through regulatory cells: From mice to men. Immunol Rev 2014; 258: 102-116.
12. Fuchs EJ,. Transplantation tolerance: From theory to clinic. Immunol Rev 2014; 258: 64-79.
13. Miyara M, Yoshioka Y, Kitoh A, et al., Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
14. Schmidl C, Hansmann L, Lassmann T, et al., The enhancer and promoter landscape of human regulatory and conventional T cell subpopulations. Blood 2014; 123: e68-e78.
15. Braza F, Dugast E, Panov I, et al., Central role of CD45RA- Foxp3hi memory regulatory T cells in clinical kidney transplantation tolerance. J Am Soc Nephrol 2015. doi: 10.1681/ASN.2014050480
16. Duhen T, Duhen R, Lanzavecchia A, Sallusto F, Campbell DJ,. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 2012; 119: 4430-4440.
17. Shevach EM,. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30: 636-645.
18. Campbell DJ, Koch MA,. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 2011; 11: 119-130.
19. Sawant DV, Vignali DA,. Once a Treg, always a Treg? Immunol Rev 2014; 259: 173-191.
20. Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I,. Rapamycin and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107: 1018-1023.
21. Kawai M, Kitade H, Mathieu C, Waer M, Pirenne J,. Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation 2005; 79: 1073-1077.
22. Floess S, Freyer J, Siewert C, et al., Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5: e38.
23. Morikawa H, Ohkura N, Vandenbon A, et al., Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation. Proc Natl Acad Sci USA 2014; 111: 5289-5294.
24. Ohkura N, Hamaguchi M, Morikawa H, et al., T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 2012; 37: 785-799.
25. Baron U, Floess S, Wieczorek G, et al., DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37: 2378-2389.
26. Rudra D, deRoos P, Chaudhry A, et al., Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat Immunol 2012; 13: 1010-1019.
27. Fu W, Ergun A, Lu T, et al., A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. Nat Immunol 2012; 13: 972-980.
28. Ouyang W, Liao W, Luo CT, et al., Novel Foxo1-dependent transcriptional programs control T(reg) cell function. Nature 2012; 491: 554-559.
29. Bestard O, Cruzado JM, Rama I, et al., Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008; 19: 2020-2026.
30. Bestard O, Cunetti L, Cruzado JM, et al., Intragraft regulatory T cells in protocol biopsies retain foxp3 demethylation and are protective biomarkers for kidney graft outcome. Am J Transplant 2011; 11: 2162-2172.
31. Sakaguchi S, Miyara M, Costantino CM, Hafler DA,. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490-500.
32. Liu W, Putnam AL, Xu-Yu Z, et al., CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701-1711.
33. Maecker HT, McCoy JP, Nussenblatt R,. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol 2012; 12: 191-200.
34. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M,. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 2005; 115: 1953-1962.
35. Ayyoub M, Raffin C, Valmori D,. Comment on "helios+ and helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans". J Immunol 2013; 190: 4439-4440.
36. Raffin C, Pignon P, Celse C, Debien E, Valmori D, Ayyoub M,. Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1beta by downregulating their suppressor functions. J Immunol 2013; 191: 4619-4627.
37. Sanchez Rodriguez R, Pauli ML, Neuhaus IM, et al., Memory regulatory T cells reside in human skin. J Clin Invest 2014; 124: 1027-1036.
38. Dwyer KM, Hanidziar D, Putheti P, et al., Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant 2010; 10: 2410-2420.
39. Baecher-Allan C, Wolf E, Hafler DA,. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006; 176: 4622-4631.
40. Schaier M, Seissler N, Schmitt E, et al., DR(high+)CD45RA(-)-Tregs potentially affect the suppressive activity of the total Treg pool in renal transplant patients. PLoS ONE 2012; 7: e34208.
41. Pesenacker AM, Broady R, Levings MK,. Control of tissue-localized immune responses by human regulatory T cells. Eur J Immunol 2015; 45: 333-343.
42. Linterman MA, Pierson W, Lee SK, et al., Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med 2011; 17: 975-982.
43. Grimbert P, Mansour H, Desvaux D, et al., The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection. Transplantation 2007; 83: 341-346.
44. Mansour H, Homs S, Desvaux D, et al., Intragraft levels of Foxp3 mRNA predict progression in renal transplants with borderline change. J Am Soc Nephrol 2008; 19: 2277-2281.
45. Bestard O, Cruzado JM, Mestre M, et al., Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007; 179: 4901-4909.
46. Ashton-Chess J, Dugast E, Colvin RB, et al., Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol 2009; 20: 1113-1122.
47. Muthukumar T, Dadhania D, Ding R, et al., Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342-2351.
48. Veronese F, Rotman S, Smith RN, et al., Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection. Am J Transplant 2007; 7: 914-922.
49. Ziegler SF,. FOXP3: Not just for regulatory T cells anymore. Eur J Immunol 2007; 37: 21-23.
50. Wieczorek G, Asemissen A, Model F, et al., Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009; 69: 599-608.
51. De Serres SA, Sayegh MH, Najafian N,. Immunosuppressive drugs and Tregs: A critical evaluation! Clin. J Am Soc Nephrol 2009; 4: 1661-1669.
52. Fanigliulo D, Lazzerini PE, Capecchi PL, Ulivieri C, Baldari CT, Laghi-Pasini F,. Clinically-relevant cyclosporin and rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: An in-vitro study in healthy humans. Int Immunopharmacol 2014; 24: 276-284.
53. Akimova T, Kamath BM, Goebel JW, et al., Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. Am J Transplant 2012; 12: 3449-3461.
54. Battaglia M, Stabilini A, Roncarolo MG,. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 4743-4748.
55. Hester J, Schiopu A, Nadig SN, Wood KJ,. Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am J Transplant 2012; 12: 2008-2016.
56. Rossetti M, Spreafico R, Saidin S, et al., Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region. J Immunol 2015; 194: 113-124.
57. Orlando G, Hematti P, Stratta RJ, et al., Clinical operational tolerance after renal transplantation: Current status and future challenges. Ann Surg 2010; 252: 915-928.
58. Brouard S, Pallier A, Renaudin K, et al., The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases. Am J Transplant 2012; 12: 3296-3307.
59. Newell KA, Asare A, Kirk AD, et al., Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836-1847.
60. Sagoo P, Perucha E, Sawitzki B, et al., Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848-1861.
61. Braza F, Soulillou JP, Brouard S,. Gene expression signature in transplantation tolerance. Clin Chim Acta 2012; 413: 1414-1418.
62. Brouard S, Mansfield E, Braud C, et al., Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104: 15448-15453.
63. Pallier A, Hillion S, Danger R, et al., Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78: 503-513.
64. Baron D, Ramstein G, Chesneau M, et al., A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft. Kidney Int 2015; 87: 984-995.
65. Moraes-Vieira PM, Takenaka MC, Silva HM, et al., GATA3 and a dominant regulatory gene expression profile discriminate operational tolerance in human transplantation. Clin Immunol 2012; 142: 117-126.
66. Chesneau M, Pallier A, Braza F, et al., Unique B cell differentiation profile in tolerant kidney transplant patients. Am J Transplant 2014; 14: 144-155.
67. Silva HM, Takenaka MC, Moraes- Vieira PM, et al., Preserving the B cell compartment favors operational tolerance in human renal transplantation. Mol Med 2012; 18: 733-743.
68. Braudeau C, Racape M, Giral M, et al., Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int 2007; 20: 845-855.
69. Louis S, Braudeau C, Giral M, et al., Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81: 398-407.
70. Becker LE, de Oliveira Biazotto F, Conrad H, et al., Cellular infiltrates and NFkappaB subunit c-Rel signaling in kidney allografts of patients with clinical operational tolerance. Transplantation 2012; 94: 729-737.
71. Roussey-Kesler G, Giral M, Moreau A, et al., Clinical operational tolerance after kidney transplantation. Am J Transplant 2006; 6: 736-746.
72. Danger R, Pallier A, Giral M, et al., Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant. J Am Soc Nephrol 2012; 23: 597-606.
73. Scandling JD, Busque S, Dejbakhsh-Jones S, et al., Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant 2012; 12: 1133-1145.
74. Kawai T, Sachs DH, Sykes M, Cosimi AB,. Immune Tolerance N. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2013; 368: 1850-1852.
75. Andreola G, Chittenden M, Shaffer J, et al., Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation. Am J Transplant 2011; 11: 1236-1247.
76. Leventhal J, Abecassis M, Miller J, et al., Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4: 124ra 28.
77. Leventhal J, Abecassis M, Miller J, et al., Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: Durable chimerism predicts outcome. Transplantation 2013; 95: 169-176.
78. Huang Y, Bozulic LD, Miller T, Xu H, Hussain LR, Ildstad ST,. CD8α+ plasmacytoid precursor DCs induce antigen-specific regulatory T cells that enhance HSC engraftment in vivo. Blood 2011; 117: 2494-2505.
79. Liang B, Workman C, Lee J, et al., Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008; 180: 5916-5926.
80. Haudebourg T, Dugast AS, Coulon F, Usal C, Triebel F, Vanhove B,. Depletion of LAG-3 positive cells in cardiac allograft reveals their role in rejection and tolerance. Transplantation 2007; 84: 1500-1506.
81. Krummey SM, Ford ML,. Braking bad: Novel mechanisms of CTLA-4 inhibition of T cell responses. Am J Transplant 2014; 14: 2685-2690.
82. Kuehn HS, Ouyang W, Lo B, et al., Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014; 345: 1623-1627.
83. Schubert D, Bode C, Kenefeck R, et al., Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014; 20: 1410-1416.
84. Bettini M, Vignali DA,. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 2009; 21: 612-618.
85. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, et al., Human allograft acceptance is associated with immune regulation. J Clin Invest 2000; 106: 145-155.
86. Haynes LD, Jankowska-Gan E, Sheka A, et al., Donor-specific indirect pathway analysis reveals a B cell-independent signature which reflects outcomes in kidney transplant recipients. Am J Transplant 2012; 12: 640-648.
87. Borsellino G, Kleinewietfeld M, Di Mitri D, et al., Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110: 1225-1232.
88. Mandapathil M, Hilldorfer B, Szczepanski MJ, et al., Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 2010; 285: 7176-7186.
89. Fletcher JM, Lonergan R, Costelloe L, et al., CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009; 183: 7602-7610.
90. Kinsey GR, Huang L, Jaworska K, et al., Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol 2012; 23: 1528-1537.
91. Deaglio S, Dwyer KM, Gao W, et al., Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
92. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, et al., Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 2013; 39: 949-962.
93. Komatsu N, Okamoto K, Sawa S, et al., Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 2014; 20: 62-68.
94. Zhou X, Bailey-Bucktrout SL, Jeker LT, et al., Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10: 1000-1007.
95. Degauque N, Mariat C, Kenny J, et al., Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest 2008; 118: 735-741.
96. Vu MD, Xiao X, Gao W, et al., OX40 costimulation turns off Foxp3+ Tregs. Blood 2007; 110: 2501-2510.
97. Sharma MD, Huang L, Choi JH, et al., An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity 2013; 38: 998-1012.
98. Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H,. The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013; 13: 461-467.
99. Miyao T, Floess S, Setoguchi R, et al., Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 2012; 36: 262-275.
100. Hoffmann P, Boeld TJ, Eder R, et al., Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 2009; 39: 1088-1097.
101. Hoffmann P, Eder R, Boeld TJ, et al., Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T cell lines upon in vitro expansion. Blood 2006; 108: 4260-4267.
102. Valmori D, Raffin C, Raimbaud I, Ayyoub M,. Human RORgammat+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors. Proc Natl Acad Sci USA 2010; 107: 19402-19407.
103. Mantel PY, Kuipers H, Boyman O, et al., GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007; 5: e329.
104. MacDonald KG, Dawson NA, Huang Q, Dunne JV, Levings MK, Broady R,. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. J Allergy Clin Immunol 2015; 135: 946-e9.
105. Nie H, Zheng Y, Li R, et al., Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med 2013; 19: 322-328.
106. Thaunat O, Graff-Dubois S, Fabien N, et al., A stepwise breakdown of B cell tolerance occurs within renal allografts during chronic rejection. Kidney Int 2012; 81: 207-219.
107. Beriou G, Costantino CM, Ashley CW, et al., IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009; 113: 4240-4249.
108. Dominguez-Villar M, Baecher-Allan CM, Hafler DA,. Identification of T helper type 1- like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med 2011; 17: 673-675.
109. McClymont SA, Putnam AL, Lee MR, et al., Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 2011; 186: 3918-3926.
110. Redjimi N, Raffin C, Raimbaud I, et al., CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res 2012; 72: 4351-4360.
111. Juvet SC, Whatcott AG, Bushell AR, Wood KJ,. Harnessing regulatory T cells for clinical use in transplantation: The end of the beginning. Am J Transplant 2014; 14: 750-763.
112. Samstein RM, Arvey A, Josefowicz SZ, et al., Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. Cell 2012; 151: 153-166.
113. Feng Y, Arvey A, Chinen T, van der Veeken J, Gasteiger G, Rudensky AY,. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell 2014; 158: 749-763.
114. Schmidl C, Klug M, Boeld TJ, et al., Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res 2009; 19: 1165-1174.
115. Hippen KL, Riley JL, June CH, Blazar BR,. Clinical perspectives for regulatory T cells in transplantation tolerance. Semin Immunol 2011; 23: 462-468.
116. Wang L, Liu Y, Beier UH, et al., Foxp3+ T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity. Blood 2013; 121: 3631-3639.
117. Huynh A, Zhang R, Turka LA,. Signals and pathways controlling regulatory T cells. Immunol Rev 2014; 258: 117-131.
118. Pollizzi KN, Powell JD,. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol 2014; 14: 435-446.
119. Dang EV, Barbi J, Yang HY, et al., Control of T(H) 17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011; 146: 772-784.
120. Shi LZ, Wang R, Huang G, et al., HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med 2011; 208: 1367-1376.
121. Clambey ET, McNamee EN, Westrich JA, et al., Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA 2012; 109: E2784-E2793.
122. Delgoffe GM, Kole TP, Zheng Y, et al., The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 30: 832-844.
123. Liu G, Yang K, Burns S, Shrestha S, Chi H,. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H) 1 and T(reg) cells. Nat Immunol 2010; 11: 1047-1056.
124. Burzyn D, Kuswanto W, Kolodin D, et al., A special population of regulatory T cells potentiates muscle repair. Cell 2013; 155: 1282-1295.
125. Cipolletta D, Kolodin D, Benoist C, Mathis D,. Tissular T(regs): A unique population of adipose-tissue-resident Foxp3+CD4+ T cells that impacts organismal metabolism. Semin Immunol 2011; 23: 431-437.
126. Exley MA, Hand L, O'Shea D, Lynch L,. Interplay between the immune system and adipose tissue in obesity. J Endocrinol 2014; 223: R41-R48.
127. Ford ML,. Literature Watch Implications for transplantation. Am J Transplant 2015; 15: 853.
128. Kolodin D, van Panhuys N, Li C, et al., Antigen-and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. Cell Metab 2015; 21: 543-557.
129. Vasanthakumar A, Moro K, Xin A, et al., The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue- resident regulatory T cells. Nat Immunol 2015; 16: 276-285.
130. Han JM, Wu D, Denroche HC, Yao Y, Verchere CB, Levings MK,. IL-33 reverses an obesity-induced deficit in visceral adipose tissue ST2+ T regulatory cells and ameliorates adipose tissue inflammation and insulin resistance. J Immunol 2015; 194: 4777-4783.
131. van Loosdregt J, Vercoulen Y, Guichelaar T, et al., Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010; 115: 965-974.
132. Tao R, de Zoeten EF, Ozkaynak E, et al., Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13: 1299-1307.
133. Choi SW, Braun T, Chang L, et al., Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: A phase 1/2 trial. Lancet Oncol 2014; 15: 87-95.
134. Choi SW, Gatza E, Hou G, et al., Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood 2015; 125: 815-819.
135. de Zoeten EF, Wang L, Butler K, et al., Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 2011; 31: 2066-2078.
136. Wang L, Liu Y, Han R, et al., FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3. J Clin Invest 2015; 125: 1111-1123.